Aprea Therapeutics Inc. (APRE)
$0.80
$-0.02
(-2.49%)
As on 03-Sep-2026 13:32EDT
Market cap
$11 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.3
-
Face value
--
-
Shares outstanding
12,591,136
7 Years Aggregate
CFO
$-172.64 Mln
EBITDA
$-130.64 Mln
Net Profit
$-386.74 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aprea Therapeutics (APRE)
| -6.3 | 29.0 | 4.6 | -49.1 | -40.4 | -61.6 | -- |
|
BSE Sensex
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Aprea Therapeutics (APRE)
| -74.1 | -29.8 | -29.0 | -88.5 | -41.7 | -89.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aprea Therapeutics (APRE)
|
0.8 | 10.6 | 0.0 | -12.3 | -237,362.8 | -48.3 | -- | 0.3 |
| 85.3 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 271.6 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 73.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.3 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 370.3 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 543.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 586.9 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 356.0 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Aprea Therapeutics (APRE)
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051,... an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania. Read more
-
Co-Founder, CEO, President & Director
Dr. Oren Gilad Ph.D.
-
Co-Founder, CEO, President & Director
Dr. Oren Gilad Ph.D.
-
Headquarters
Doylestown, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Aprea Therapeutics (APRE)
What is the current share price of Aprea Therapeutics Inc (APRE) Today?
The share price of Aprea Therapeutics Inc (APRE) is $0.80 (NASDAQ) as of 03-Sep-2026 13:32 EDT. Aprea Therapeutics Inc (APRE) has given a return of -40.42% in the last 3 years.
What is the current PB & PE ratio of Aprea Therapeutics Inc (APRE)?
Since, TTM earnings of Aprea Therapeutics Inc (APRE) is negative, P/E ratio is not available.
The P/B ratio of Aprea Therapeutics Inc (APRE) is 0.28 times as on 28-Aug-2026, a 95 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.52 |
0.53 |
2024 |
-1.51 |
1.01 |
2023 |
-1.23 |
0.96 |
2022 |
-0.01 |
0.05 |
2021 |
-0.08 |
0.06 |
What is the 52 Week High and Low of Aprea Therapeutics Inc (APRE)?
The 52-week high and low of Aprea Therapeutics Inc (APRE) are Rs 1.69 and Rs 0.55 as of 04-Sep-2026.
What is the market cap of Aprea Therapeutics Inc (APRE)?
Aprea Therapeutics Inc (APRE) has a market capitalisation of $ 11 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Aprea Therapeutics Inc (APRE)?
Before investing in Aprea Therapeutics Inc (APRE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.